These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1630017)

  • 1. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)].
    Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A
    Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
    Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
    Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New protocols for myeloma chemotherapy plus IFN alpha].
    Kitani T
    Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy of multiple myeloma].
    Uzuka Y; Saito Y; Ito T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
    Shimamoto Y; Matsuzaki M; Ono K; Sano M; Yamaguchi M
    Haematologia (Budap); 1991; 24(1):9-11. PubMed ID: 1813363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
    Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
    Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma].
    Hoshino S; Saito H; Wada M; Akutsu M; Shiozaki H; Takanashi M; Takei Y; Tanaka S; Teramura M; Takada K
    Rinsho Ketsueki; 1987 Mar; 28(3):358-65. PubMed ID: 3475485
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complete remission in multiple myeloma with natural interferon-alpha (HLBI) and melphalan/prednisolone intermittent therapy].
    Ito M; Nakagawa T; Imoto S; Isobe T; Nakao Y
    Rinsho Ketsueki; 1990 Jun; 31(6):847-52. PubMed ID: 2214176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
    Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
    Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
    Ahre A; Björkholm M; Mellstedt H; Brenning G; Engstedt L; Gahrton G; Gyllenhammar H; Holm G; Johansson B; Järnmark M
    Cancer Treat Rep; 1984 Nov; 68(11):1331-8. PubMed ID: 6388832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
    Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma].
    Hara M; Nakamura T; Fujii Y
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.